The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are approved by BPS as a provider for the recertification of BCOP.
BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/
To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.
The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.
In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.
The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.
Target Audience: These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in: Acute Leukemia, Adult Sarcoma, Breast Cancer, Cancers of the GI tract, Chronic Leukemia, Graft-versus-Host Disease, Lung Cancer, Ovarian Cancer, Pediatric Malignancy, Statistics, Urothelial Carcinoma.
Oncology Home Study Syllabus Module A: Acute Leukemia, Chronic Leukemia, and Graft-versus-Host DiseaseActivity Number: 0204-9999-26-937-H01-P
Contact Hour(s): 4.50
Activity Type: Application BasedLearning ObjectivesAcute Leukemia
Jabbour EJ, Kantarjian HM, Goekbuget N, et al. Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab. Blood Cancer J. 2024;14(1):203.
- Select an appropriate frontline chemotherapy backbone for adults with Ph-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) based on age, fitness, comorbidities, and functional status.
- Compare common frontline ALL regimens to identify major toxicity drivers and practical treatment implications across phases of care.
Chronic Leukemia
Sharman JP, Munir T, Grosicki S, et al. Phase III trial of pirtobrutinib versus idelalisib/rituximab or bendamustine/rituximab in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (BRUIN CLL-321). J Clin Oncol. 2025;43(22):2538-49.
- Describe the BRUIN CLL-321 trial of pirtobrutinib for the treatment of chronic lymphocytic leukemia after the receipt of a covalent Bruton tyrosine kinase inhibitor.
- Develop recommendations for the use of pirtobrutinib for the treatment of chronic lymphocytic leukemia after the receipt of a covalent Bruton tyrosine kinase inhibitor as reported in the BRUIN CLL-321 trial.
Graft-versus-Host Disease
Wolff D, Cutler C, Lee SJ, et al. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2024;391(11):1002-1014.
- Describe the study of axatilimab for refractory chronic graft-versus-host disease in patients following allogeneic hematopoietic cell transplantation.
- Develop recommendations for the use of axatilimab in patients with refractory chronic graft-versus-host disease.
- Select appropriate patients to receive axatilimab for refractory chronic graft-versus-host disease based on the results of the AGAVE-201 trial.
|
Oncology Home Study Syllabus Module B: Urothelial Carcinoma, Ovarian Cancer, and Adult SarcomaActivity Number: 0204-9999-26-938-H01-P
Contact Hour(s): 4.00
Activity Type: Application BasedLearning ObjectivesUrothelial Carcinoma
Apolo AB, Ballman KV, Sonpavde G, et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl J Med. 2025;392(1):45-55.
- Describe the study by Apolo and colleagues of adjuvant pembrolizumab vs. observation for muscle-invasive urothelial carcinoma.
- Develop recommendations for the use of adjuvant pembrolizumab in patients with newly diagnosed muscle-invasive bladder cancer.
- Select appropriate patients to receive adjuvant pembrolizumab based on the results of the AMBASSADOR trial by Apolo et al.
Ovarian Cancer
Susana N. Banerjee et al.Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol 43, 2782-2792(2025).
- Describe the study of avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer.
- Develop recommendations for the use of avutometinib with defactinib in patients with recurrent low-grade serous ovarian cancer.
- Select appropriate patient to receive avutometinib with defactinib according to the results of the RAMP 201 study.
Adult Sarcoma
Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388(10):898-912.
- Describe the design and key efficacy outcomes of the DeFi trial evaluating nirogacestat in adults with progressing desmoid tumors.
- Apply DeFi trial efficacy and patient-reported outcome data to clinical decision-making for patients with progressing desmoid tumors.
- Develop monitoring and management strategies for toxicities associated with nirogacestat, including gastrointestinal effects, electrolyte abnormalities, and ovarian dysfunction.
|
Oncology Home Study Syllabus Module C: Lung Cancer, Pediatric Malignancy, and Breast CancerActivity Number: 0204-9999-26-939-H01-P
Contact Hour(s): 4.50
Activity Type: Application BasedLearning ObjectivesLung Cancer
Su PL, Furuya N, Asrar A, et al. Recent advances in therapeutic strategies for non-small cell lung cancer. J Hematology & Oncology. 2025;18:35;1-30.
- Describe the therapeutic strategies available for patients with advanced non-small cell lung cancer.
- Develop recommendations for the treatment of advanced non-small cell lung cancer based on the results of the landmark trials described within the review.
-
Select appropriate patients to receive targeted therapy, immunotherapy, and cytotoxic therapy based on the results of the landmark trials presented within the review.
Pediatric Malignancy
Issa GC, Aldoss I, Thirman MJ, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2024; 43(1): 75-84.
- Describe the study of revumenib for relapsed or refractory acute leukemias.
- Develop recommendations for the use of revumenib in patients with relapsed or refractory acute leukemias.
-
Select appropriate patients to receive revumenib therapy based on the results of the study by Issa, et al.
Breast Cancer
Loibl S, Park YH, Shao Z, et al; for the DESTINY-Breast05 Trial Investigators. Trastuzumab deruxtecan in residual HER2-positive early breast cancer—correction. N Engl J Med. 2026;394(13):1352.
- Describe the DESTINY-Breast05 study of trastuzumab deruxtecan for the adjuvant treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer at high risk for recurrence.
- Develop recommendations for the use of trastuzumab deruxtecan in patients with early stage HER2-positive breast cancer.
- Select appropriate patients to receive trastuzumab deruxtecan based on the results of the DESTINY-Breast05 trial.
|
Oncology Home Study Syllabus Module D: Statistics and Cancers of the GI tractActivity Number: 0204-9999-26-940-H01-P
Contact Hour(s): 3.00
Activity Type: Application BasedLearning ObjectivesStatistics
Paul J, Barari M. Meta‐analysis and traditional systematic literature reviews—what, why, when, where, and how? Psychol Mark. 2022;39(6):1099-1115.
Ji X, Wang G, Pan D, Xu S, Lei X. Efficacy and safety of pembrolizumab in advanced gastric and gastroesophageal junction cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2025;25(1):173.
- Explain the differences between a systematic review and meta-analysis.
- Critique the methodology used for a systematic review or meta-analysis.
- Evaluate the results of a systematic review or meta-analysis.
Cancers of the GI tract
Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393(3):217-230.
- Describe the MATTERHORN trial comparing durvalumab and FLOT (5-fluorouracil/leucovorin, oxaliplatin, docetaxel) to FLOT alone as perioperative therapy for gastric and gastroesophageal junction cancers.
- Develop recommendations for the use of durvalumab and FLOT as perioperative therapy for gastric and gastroesophageal junction cancers based on the MATTERHORN trial.
- Select appropriate patients to receive durvalumab and FLOT based on the MATTERHORN trial.
|
2026 Oncology Home Study Syllabus - Recert - Modules A-DActivity Number:
Contact Hour(s):
Activity Type: Knowledge Based |
The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.